Through
4/26
While the world works to flatten the curve, scientists at Penn and Wistar hope to deliver the COVID-19 pandemic’s silver bullet: a vaccine that effectively protects people from infection.
Penn researchers have shown success using genetically engineered macrophages, an immune cell that eats invaders in the body, to target solid tumors.
A Penn study shows a better clinical response to immunotherapy correlates with higher ratio of tumor mutations detected by a liquid biopsy.
In the first U.S. clinical trial, cells removed from patients and brought back into the lab were able to kill cancer months after their original manufacturing and infusion.
A new study identifies the mechanism that prevents cell death, and can guide future immunotherapy strategies in patients whose blood cancers are resistant to CAR T therapy.
By using messenger RNA across the T cell’s membrane via a nanoparticle instead of a DNA-rewriting virus on extracted T cells, CAR T treatments could have fewer side effects.
Faculty at the School of Veterinary Medicine target neglected tropical diseases with advanced science, cross-disciplinary collaborations, and work in the lab and the field.
Genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology, then infusing those cells back into the patient appears safe and feasible based on early data from the first-ever clinical trial to test the approach in humans in the United States.
With CAR T cell therapy, a patient’s own immune cells are genetically modified and inserted back into the body to find and kill cancer. Now scientists have now discovered a new way to track CAR T cells in the body.
Knowing which T cells will lose the battle against cancer earlier could inform treatments and the development of new immunotherapies.
Nobel laureates Katalin Karikó and Drew Weissman of the Perelman School of Medicine appear on “Sunday Morning” to discuss their careers, their mRNA research, and the COVID-19 vaccines.
FULL STORY →
Virginia Man-Yee Lee of the Perelman School of Medicine says it’s likely in the future that anyone older than 60 will get an Alzheimer’s test.
FULL STORY →
Daiwei Zhang and Mingyao Li of the Perelman School of Medicine and colleagues have developed an AI tool called iStar that can automatically spot tumors and types of cancer that are difficult for clinicians to see or identify and can predict candidates for immunotherapy.
FULL STORY →
Drew Weissman of the Perelman School of Medicine, who won the Nobel Prize for mRNA vaccines along with Katalin Karikó, is researching an mRNA vaccine against cancer.
FULL STORY →
Scott Hensley of the Perelman School of Medicine is working on a flu vaccine to provide protection against 20 subtypes of flu that may pose a pandemic threat in the future.
FULL STORY →
Carl June of the Perelman School of Medicine praises New Zealand research into a new CAR T-cell cancer treatment for patients with blood cancer.
FULL STORY →